PHOSPRINT IDIOTIKI KEFALAIOUXIKIETAIREIA

Their core work

PhosPrint is a Greek bioprinting technology company whose core capability is laser-induced forward transfer (LIFT) — a technique that uses laser pulses to deposit living cells and biological materials with high spatial precision. They apply this technology along two tracks: building organ-on-chip platforms that recreate tumor microenvironments for cancer research, and printing functional tissue constructs (such as a fully autologous urinary bladder) intended for transplantation. The company name itself reflects this identity — "Phos" (Greek for light) combined with "Print" signals laser-driven biofabrication. In consortia they act as the specialist technology provider, contributing proprietary printing capabilities that other academic and clinical partners cannot replicate in-house.

What they specialise in

How they've shifted over time

Both H2020 projects began in 2021, so PhosPrint has no true long-term funding history to trace — the "early vs recent" keyword split reflects two parallel application tracks rather than genuine temporal change. The first track (organ-on-chip, tumor migration, microfluidics) targets research instrumentation for oncology, while the second (laser bioprinting, autologous biomaterials, in vivo printing) targets regenerative medicine and clinical transplantation. What this reveals is a deliberate two-pronged strategy: selling research tools to labs on one side and pursuing clinical tissue manufacturing on the other. If this pattern holds, the likely trajectory is deeper investment in in vivo bioprinting as that field matures toward clinical trials.

PhosPrint appears to be moving from providing research models toward clinically applicable bioprinted tissue constructs, with in vivo laser bioprinting as the technology differentiator that could position them in the regenerative medicine supply chain.

How they like to work

PhosPrint has never held a coordinator role — in both projects they join as a specialist contributor (participant or third party), which is typical for a small company whose value lies in a specific proprietary technology rather than project management. Despite their size, they operate in relatively broad consortia: 15 unique partners across 10 countries suggests they are sought out repeatedly as a technology node rather than a general research partner. This pattern indicates that working with PhosPrint means buying access to their laser bioprinting capability, not co-directing a project.

PhosPrint has built connections with 15 consortium partners across 10 countries through just two projects, suggesting efficient network building within the biomedical and nanotechnology communities. Their FET and NANO pillar affiliations point toward partnerships with frontier research groups rather than industrial manufacturers.

What sets them apart

PhosPrint occupies an unusual niche for a Greek SME: laser-based bioprinting is a capital- and expertise-intensive field dominated by larger Northern European and North American players, making a Greek specialist company in this space genuinely rare. Their dual coverage of cancer research models and transplantable organ constructs means they can serve both the life-science tools market and the regenerative medicine pipeline — a combination that broadens their relevance to consortium builders. For a partner seeking hands-on LIFT bioprinting execution capacity rather than theoretical expertise, PhosPrint is one of very few SMEs in Southern Europe that can actually deliver printed biological constructs.

Highlights from their portfolio

• Tumor-LN-oC
  PhosPrint's only directly funded H2020 project (EUR 284,856), combining bioprinting with microfluidics to recreate the tumor-lymph node interface — a technically demanding cancer research platform with clear commercial potential in drug testing.
• UroPrint
  Positions PhosPrint in the highly ambitious space of printing transplantable organs from a patient's own cells, using in vivo laser bioprinting techniques that remain at the frontier of regenerative medicine.